EDGAR·FLOW

Xtant Medical Holdings, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 72/100
What the filing says
Xtant Medical reported Q3 2026 revenue of $24.3M (down 27% from $33.3M in Q3 2025), marking the second consecutive quarter missing guidance. The board announced an active strategic review evaluating operational improvements, partnerships, restructuring, M&A, divestitures, and financing alternatives—with no timetable set. The company withdrew full-year 2026 guidance. Core biologics grew 13% YoY to $19.3M, but gross margin compressed 970 basis points YoY to 56.3% due to lost wound-care licensing revenue ($5.5M absent) and mix shift. Cash declined to $7.8M from $17.1M; total debt is $22M. The company expects 12+ months of runway.
Why this rating

Strategic review and dual guidance miss represent material uncertainty for a $45M-cap company. 27% YoY revenue decline and cash burn ($9.3M nine-month decline) are business-threatening. Biologics growth partially offsets. Event is significant but not yet existential.

Tradability signal
NO TRADE

No trade: price $0.21 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
before filing · preread
$0.27 ▲ 0.04%
at our read · unknown
$0.27
+10 min · unknown
$0.18 ▼ 32.72%
+30 min · unknown
$0.20 ▼ 26.57%
+1 hr · unknown
$0.21 ▼ 23.08%
+4 hrs · unknown
$0.18 ▼ 33.64%

The stock had already moved -0.04% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ XTNT · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.